Defence Therapeutics Inc
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more
Market Cap & Net Worth: Defence Therapeutics Inc (DTCFF)
Defence Therapeutics Inc (OTCQB:DTCFF) has a market capitalization of $54.53 Million ($54.53 Million) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #24956 globally and #8555 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Defence Therapeutics Inc's stock price $1.00 by its total outstanding shares 54725370 (54.73 Million).
Defence Therapeutics Inc Market Cap History: 2021 to 2025
Defence Therapeutics Inc's market capitalization history from 2021 to 2025. Data shows change from $228.75 Million to $54.53 Million (-21.10% CAGR).
Defence Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Defence Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DTCFF by Market Capitalization
Companies near Defence Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Defence Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Defence Therapeutics Inc Historical Marketcap From 2021 to 2025
Between 2021 and today, Defence Therapeutics Inc's market cap moved from $228.75 Million to $ 54.53 Million, with a yearly change of -21.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $54.53 Million | +143.44% |
| 2024 | $22.40 Million | -75.19% |
| 2023 | $90.30 Million | -2.94% |
| 2022 | $93.03 Million | -59.33% |
| 2021 | $228.75 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Defence Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $54.53 Million USD |
| MoneyControl | $54.53 Million USD |
| MarketWatch | $54.53 Million USD |
| marketcap.company | $54.53 Million USD |
| Reuters | $54.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.